

BioSpect


the business of BioSpect

24 years of leveraging the business of BioSpect
www.biospectrumindia.com

Johnson & Johnson launches new TECNIS Odyssey next-gen intraocular lens in India

13 March 2026 | News

Offering cataract patients precise vision at every distance in any lighting



Johnson & Johnson is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of TECNIS Odyssey IOL in India. The new full visual range IOL offers high-quality and continuous vision with unmatched range.

This will allow patients to see clearly from far to near and in between, minimising their need for glasses. Built on the industry-leading TECNIS platform, combining advanced optics and proprietary materials, TECNIS Odyssey IOL offers consistently clear, high-contrast vision.

TECNIS Odyssey is engineered for surgeon confidence as Freeform diffractive profile contributes to enhanced tolerance to residual refractive errors. 94% of patients were satisfied with their overall vision without glasses.

Freeform diffractive profile contributes to a low incidence of bothersome visual disturbances. 93% of patients either did not report any visual disturbances.

TECNIS Odyssey delivers superior low light contrast. 92% satisfaction with ability to see steps and curbs at night. With a variety of options for different visual needs and lifestyles, the TECNIS platform empowers more patients to find the right solution. This year marks the 25th anniversary of TECNIS innovation at Johnson & Johnson.

"The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence. Its introduction in India expands access to advanced IOL technology designed to deliver high-quality, continuous vision across distances. Together with TECNIS PureSee, TECNIS Odyssey IOL elevates the strength and depth of our IOL portfolio, helping us meet the diverse needs of today's aging population," said Burzin Shahana, Country Manager, Surgical Vision India & South Asia, Johnson & Johnson.